In this column for the JAMA Health Forum, Larry Levitt examines how the No Surprises Act that prohibits unexpected out-of-network charges for patients could lead to lower payment rates and revenues for some doctors and other care providers.
- view as grid
- view as list
In this Axios column, Drew Altman examines the data about what parents say they will do once their children ages 5-11 become eligible for a COVID-19 vaccine, and why it will take some time and a concerted outreach effort to match adult vaccination rates.
In this column for the JAMA Health Forum, Larry Levitt explores why the Medicaid “coverage gap” still exists in 12 states that have not expanded their Medicaid programs under the Affordable Care Act, why it matters, and why eliminating it could prove challenging.
In this Axios column, Drew Altman takes on the idea that communities of color are behind the problem of the unvaccinated in the U.S.
In this Axios column, Drew Altman examines the lessons for COVID-19 as a political issue from Governor Gavin Newsom’s resounding win in California’s recall election.
In his latest Axios column, Drew Altman shows that parents feel that children have fared better during COVID attending school in-person than virtually in terms of academic performance and their mental health and wellbeing.
In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
With much focus on equity in the nation’s health care system during the pandemic, Drew Altman’s Axios column brings attention to warning signs about health care provided to LGBT+ individuals.
In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.